Circulating miRNA-125b Is a Potential Biomarker Predicting Response to Rituximab in Rheumatoid Arthritis
Although biologic therapies have changed the course of rheumatoid arthritis (RA), today’s major challenge remains to identify biomarkers to target treatments to selected patient groups. Circulating micro(mi)RNAs represent a novel class of molecular biomarkers whose expression is altered in RA. Our s...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2014-01-01
|
| Series: | Mediators of Inflammation |
| Online Access: | http://dx.doi.org/10.1155/2014/342524 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832545487520006144 |
|---|---|
| author | Isabelle Duroux-Richard Yves-Marie Pers Sylvie Fabre Meryem Ammari Dominique Baeten Guillaume Cartron Isabelle Touitou Christian Jorgensen Florence Apparailly |
| author_facet | Isabelle Duroux-Richard Yves-Marie Pers Sylvie Fabre Meryem Ammari Dominique Baeten Guillaume Cartron Isabelle Touitou Christian Jorgensen Florence Apparailly |
| author_sort | Isabelle Duroux-Richard |
| collection | DOAJ |
| description | Although biologic therapies have changed the course of rheumatoid arthritis (RA), today’s major challenge remains to identify biomarkers to target treatments to selected patient groups. Circulating micro(mi)RNAs represent a novel class of molecular biomarkers whose expression is altered in RA. Our study aimed at quantifying miR-125b in blood and serum samples from RA patients, comparing healthy controls and patients with other forms of rheumatic diseases and arthritis, and evaluating its predictive value as biomarker for response to rituximab. Detectable levels of miR-125b were measured in total blood and serum samples and were significantly elevated in RA patients compared to osteoarthritic and healthy donors. The increase was however also found in patients with other forms of chronic inflammatory arthritis. Importantly, high serum levels of miR-125b at disease flare were associated with good clinical response to treatment with rituximab three months later (P=0.002). This predictive value was not limited to RA as it was also found in patients with B lymphomas. Our results identify circulating miR-125b as a novel miRNA over expressed in RA and suggest that serum level of miR-125b is potential predictive biomarker of response to rituximab treatment. |
| format | Article |
| id | doaj-art-1aa66d55813b4b45ae8ecb73341231dc |
| institution | Kabale University |
| issn | 0962-9351 1466-1861 |
| language | English |
| publishDate | 2014-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Mediators of Inflammation |
| spelling | doaj-art-1aa66d55813b4b45ae8ecb73341231dc2025-02-03T07:25:33ZengWileyMediators of Inflammation0962-93511466-18612014-01-01201410.1155/2014/342524342524Circulating miRNA-125b Is a Potential Biomarker Predicting Response to Rituximab in Rheumatoid ArthritisIsabelle Duroux-Richard0Yves-Marie Pers1Sylvie Fabre2Meryem Ammari3Dominique Baeten4Guillaume Cartron5Isabelle Touitou6Christian Jorgensen7Florence Apparailly8Inserm U844, CHU Saint Eloi, Bâtiment INM, 80 Avenue Augustin Fliche, 34295 Montpellier Cedex 5, FranceInserm U844, CHU Saint Eloi, Bâtiment INM, 80 Avenue Augustin Fliche, 34295 Montpellier Cedex 5, FranceInserm U844, CHU Saint Eloi, Bâtiment INM, 80 Avenue Augustin Fliche, 34295 Montpellier Cedex 5, FranceInserm U844, CHU Saint Eloi, Bâtiment INM, 80 Avenue Augustin Fliche, 34295 Montpellier Cedex 5, FranceClinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam, 1105 AZ Amsterdam, The NetherlandsUniversité Montpellier I, UFR de Médecine, Boulevard Henri IV, 34090 Montpellier, FranceInserm U844, CHU Saint Eloi, Bâtiment INM, 80 Avenue Augustin Fliche, 34295 Montpellier Cedex 5, FranceInserm U844, CHU Saint Eloi, Bâtiment INM, 80 Avenue Augustin Fliche, 34295 Montpellier Cedex 5, FranceInserm U844, CHU Saint Eloi, Bâtiment INM, 80 Avenue Augustin Fliche, 34295 Montpellier Cedex 5, FranceAlthough biologic therapies have changed the course of rheumatoid arthritis (RA), today’s major challenge remains to identify biomarkers to target treatments to selected patient groups. Circulating micro(mi)RNAs represent a novel class of molecular biomarkers whose expression is altered in RA. Our study aimed at quantifying miR-125b in blood and serum samples from RA patients, comparing healthy controls and patients with other forms of rheumatic diseases and arthritis, and evaluating its predictive value as biomarker for response to rituximab. Detectable levels of miR-125b were measured in total blood and serum samples and were significantly elevated in RA patients compared to osteoarthritic and healthy donors. The increase was however also found in patients with other forms of chronic inflammatory arthritis. Importantly, high serum levels of miR-125b at disease flare were associated with good clinical response to treatment with rituximab three months later (P=0.002). This predictive value was not limited to RA as it was also found in patients with B lymphomas. Our results identify circulating miR-125b as a novel miRNA over expressed in RA and suggest that serum level of miR-125b is potential predictive biomarker of response to rituximab treatment.http://dx.doi.org/10.1155/2014/342524 |
| spellingShingle | Isabelle Duroux-Richard Yves-Marie Pers Sylvie Fabre Meryem Ammari Dominique Baeten Guillaume Cartron Isabelle Touitou Christian Jorgensen Florence Apparailly Circulating miRNA-125b Is a Potential Biomarker Predicting Response to Rituximab in Rheumatoid Arthritis Mediators of Inflammation |
| title | Circulating miRNA-125b Is a Potential Biomarker Predicting Response to Rituximab in Rheumatoid Arthritis |
| title_full | Circulating miRNA-125b Is a Potential Biomarker Predicting Response to Rituximab in Rheumatoid Arthritis |
| title_fullStr | Circulating miRNA-125b Is a Potential Biomarker Predicting Response to Rituximab in Rheumatoid Arthritis |
| title_full_unstemmed | Circulating miRNA-125b Is a Potential Biomarker Predicting Response to Rituximab in Rheumatoid Arthritis |
| title_short | Circulating miRNA-125b Is a Potential Biomarker Predicting Response to Rituximab in Rheumatoid Arthritis |
| title_sort | circulating mirna 125b is a potential biomarker predicting response to rituximab in rheumatoid arthritis |
| url | http://dx.doi.org/10.1155/2014/342524 |
| work_keys_str_mv | AT isabelledurouxrichard circulatingmirna125bisapotentialbiomarkerpredictingresponsetorituximabinrheumatoidarthritis AT yvesmariepers circulatingmirna125bisapotentialbiomarkerpredictingresponsetorituximabinrheumatoidarthritis AT sylviefabre circulatingmirna125bisapotentialbiomarkerpredictingresponsetorituximabinrheumatoidarthritis AT meryemammari circulatingmirna125bisapotentialbiomarkerpredictingresponsetorituximabinrheumatoidarthritis AT dominiquebaeten circulatingmirna125bisapotentialbiomarkerpredictingresponsetorituximabinrheumatoidarthritis AT guillaumecartron circulatingmirna125bisapotentialbiomarkerpredictingresponsetorituximabinrheumatoidarthritis AT isabelletouitou circulatingmirna125bisapotentialbiomarkerpredictingresponsetorituximabinrheumatoidarthritis AT christianjorgensen circulatingmirna125bisapotentialbiomarkerpredictingresponsetorituximabinrheumatoidarthritis AT florenceapparailly circulatingmirna125bisapotentialbiomarkerpredictingresponsetorituximabinrheumatoidarthritis |